Combating Misinformation with Authoritative Medical Product Information

2:15 PM - 3:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 204AB
Commissioner Califf has on numerous occasions noted combatting misinformation as a high priority (Califf RM. The FDA and the Clinical Community. JAMA. Published online August 22, 2022. doi:10.1001/jama.2022.15243) and the FDA is now partnering with the Reagan-Udall Foundation to develop strategies to combat misinformation. The COVID-19 pandemic highlighted the need for an authoritative source of information and FDA has a key role to play in providing information on medical products and they are uniquely situated to be the authoritative source for information. Current information shared by regulators post-approval is generally available on individual, siloed, and non-interoperable platforms. An integrated, interactive platform to share publicly available information on medical products can drive innovation and better-informed healthcare decisions and improve regulatory decisions whilst combating misinformation.
U.S. Lead, Global Regulatory Policy
Reagan-Udall Foundation
Vice President, Policy and Government Affairs
National Health Council
Chief Regulatory Innovation Officer
Accumulus Synergy